On October 12th, 2019, Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharm” or “the Group”) launched the Lee’s China-Europe Continuing Medical E-learning (CME) during the 30th Great Wall International Congress of Cardiology (GW-ICC) at the InterContinental Beijing Beichen Hotel. The program aims to incorporate advanced European medical resources into developing an online medical learning platform for Chinese […]
On September 4, 2019, Wen Guohui, Deputy Secretary of the CPC Guangzhou Municipal Committee, Mayor and Secretary of Guangzhou government, visited Nansha District to get a line on the construction of major projects, as well as Zhaoke Pharmaceutical Guangzhou base of Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharm” or “the Group”). Dai Xiangrong, Deputy General Manager […]
September 9, 2019, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China. The purpose of the meeting was to discuss the planed combination trial of the new drugs, anti-PD-L1 monoclonal antibody and Oncolytic virus Pexa-vec. ดาวน์โหลดข่าวฉบับเต็ม (PDF) ที่มา: Lee’s Pharmaceutical Holdings […]
On August 31st, 2019, Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharm” or “the Group”) held the 9th Perinatal Medical Forum, the first forum at Jianguo Garden Hotel, Beijing. We invited the founding member of European Association of Gynecology, member of Italian Society of Obstetrics and Gynecology, Professor Maurizio Bini of Obstetrics and Gynecology in Milan Niguarda […]
On August 20, 2019, a pre-NDA meeting for the inhalated nitric oxide (trade name: INOMAX) was held at the Drug Evaluation Center of the NMPA. Participants at the conference included Minister Ma Yunan, Vice Minister Wang Yamin, Yu Hong (senior reviewer), Liu Fuli (chief reviewer), Shi Jingfen, other reviewers and manufacturer representatives, Callie Gautreaux and […]
ROCKVILLE, Md. and Hong Kong (April 2, 2019) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), a Hong Kong based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee’s Pharm […]
ดาวน์โหลดข่าวฉบับเต็ม (PDF) ที่มา: Lee’s Pharmaceutical Holdings – News & Media
Seoul, Korea, San Francisco, Ca., Hong Kong, China —Sept. 4, 2018 — SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee’s Pharmaceutical Holdings Ltd., announced the first patient has been enrolled in China in the Phase 3 PHOCUS clinical trial of the oncolytic immunotherapy Pexa-Vec […]
Thai 
English